Par Drugs Chemicals Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Par Drugs & Chemicals Ltd is ₹ 92.88 as of 06 May 15:30 . The P/E Ratio of Par Drugs & Chemicals Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Par Drugs & Chemicals Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Par Drugs & Chemicals Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Par Drugs & Chemicals Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Par Drugs & Chemicals Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Par Drugs & Chemicals Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Par Drugs & Chemicals Ltd

Par Drugs and Chemicals Limited was originally incorporated as a Private Limited Company with the name 'Par Drugs and Chemicals Private Limited' at Bhavnagar, Gujarat on 26 February 1999.
Subsequently, the Company was converted into a Public Limited Company and the name of the Company was changed to 'Par Drugs and Chemicals Limited' on 5 November 2018. The Company began in 1982 under the vision of the founder, Late Shri Vallabhbhai J. Savani.
The Company discontinued its existing pharmaceutical and chemical operations and diversified into an entirely new vertical line of business.
With shareholder approval, the Company is investing in real estate & construction, clean & renewable energy, and capital markets. At present, Company is engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Par Drugs & Chemicals Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Par Drugs & Chemicals Ltd or Sanofi India Ltd?

Market cap of Par Drugs & Chemicals Ltd is 114 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Par Drugs & Chemicals Ltd and Sanofi India Ltd?

The stock performance of Par Drugs & Chemicals Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Par Drugs & Chemicals Ltd and Sanofi India Ltd?

As of May 6, 2026, the Par Drugs & Chemicals Ltd stock price is INR ₹92.88. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Par Drugs & Chemicals Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Par Drugs & Chemicals Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.